Cumberland Pharmaceuticals financials
$7.65−0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $37.9M | $39.6M | $42.0M | $36.0M | $37.4M | $34.4M | $29.3M | $41.2M | $33.0M |
| Gross profit | $37.9M | $31.3M | $33.5M | $32.9M | $27.2M | $28.8M | $27.0M | $23.3M | $33.8M | $27.1M |
| Gross margin | 85.0% | 82.6% | 84.7% | 78.3% | 75.5% | 76.9% | 78.4% | 79.5% | 82.1% | 82.0% |
| Operating income | -$2.8M | -$6.4M | -$8.7M | -$5.1M | -$7.7M | -$6.4M | -$9.3M | -$11.2M | -$4.1M | -$1.4M |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M | -$3.3M | -$3.5M | -$7.0M | -$8.0M | -$944.7K |
| Net margin | −6.4% | −17.1% | −15.9% | −13.3% | −9.7% | −8.9% | −10.3% | −23.7% | −19.4% | −2.9% |
| Diluted EPS | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 | $-0.22 | $-0.23 | $-0.45 | $-0.50 | $-0.06 |
| EBITDA | $1.4M | -$1.5M | -$4.6M | -$376.8K | -$3.1M | -$1.6M | -$4.9M | -$8.2M | -$1.4M | $963.8K |
| Operating cash flow | $4.9M | -$612.2K | $7.3M | $10.5M | $6.3M | $5.4M | $3.1M | $3.1M | -$557.7K | $569.5K |
| Free cash flow | $4.8M | -$678.6K | $7.1M | $10.4M | $6.2M | $5.3M | $2.8M | $2.7M | -$833.7K | $438.6K |
| Diluted shares | 14.9M | 14.1M | 14.3M | 14.6M | 14.9M | 15.2M | 15.4M | 15.6M | 15.9M | 16.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M | $24.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $5.2M | $15.3M | $12.8M | $16.2M | $15.0M | $15.0M |
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M | $96.5M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M | $49.6M |
| Shareholders' equity | $24.5M | $22.5M | $29.3M | $36.0M | $42.6M | $46.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology